A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-07-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastatictransplantdosecellmyeloma
  Phrases that lowered it: patientsprostatehcvadvanced solidbreast
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Number of arms: 5 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 22.0% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 19218 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 93.2% (raises risk) · Drug's FDA history
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 93946 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PM14 Administered Intravenously to Patients With Advanced Solid Tumors NCT05076396 · started 2017 · scored riskier than 79% of active trials completed
• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors NCT02144051 · started 2014 · scored riskier than 10% of active trials completed
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) NCT01772004 · started 2013 · scored riskier than 22% of active trials completed
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 · started 2021 · scored riskier than 70% of active trials terminated
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors NCT03685591 · started 2018 · scored riskier than 61% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.